TMV oral vaccines are designed from B16F10 and CT26 tumor cells mobilizing CD103+CD11c+ DCs by intestinal epithelial cells whose NOD2, MAPK, and NF‐κB pathways were activated and inflammatory chemokines were expressed.[246] Additionally, oral microvesicle vaccines developed from murine prostate cancer cells yielded a 5‐fold reduction in tumor volume when combined with GM‐CSF.[247]. Here, NOD2 is linked to neoplasm.